1、Artificial intelligence and its expanding role across the biopharma landscapeAn analysis of trends and developments that signal a biopharma model of the futureContents01Introduction02Deal landscape analysis03Deep dive on top 10 biopharma companies04Forward-looking AI-focused biopharma companies05Fac

2、tors impacting ongoing adoption of AI in biopharma06Conclusion07How KPMG can helpA look backA look forwardTypes of deals1 2023 KPMG LLP,a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited,a

3、private English company limited by guarantee.All rights reserved.Artificial intelligence and its expanding role across the biopharma landscapeIntroductionArtificial intelligence(AI)is already a well-established tool across biopharma.Since most AI adoption has been in research and development,as oppo

4、sed to downstream commercial operations,there are still substantial opportunities for increased integration.In addition,organizations are actively exploring how to layer generative AI,including large language models(LLMs)like OpenAIs ChatGPT,on top of existing data and AI models to further bolster t

5、he drug discovery process and augment operations.This paper provides an overview of key trends that demonstrate AIs staying power in the biopharma industry.These include top 10 biopharmas investment strategies and adoption of AI to enhance existing capabilities or bolster pipeline activities.We eval

6、uated the expanding landscape of biopharma company models,with an emphasis on AI-focused entities in the pharmaceutical and service spaces.Further,we seek to shed light on the pivotal factors affecting the acceptance and integration of these innovative paradigms by the wider biopharma community.Thes